Paper Details

  1. Home
  2. Paper Details

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

Author: CaplanS, DavisR B, DillmanR O, GottliebA J, GreenM R, KopelS, McIntyreO R, PreislerH, SchifferC, WeissR B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 326 patients with acute myeloid leukemia (AML) compared the effectiveness of cytarabine (Ara-C) at two different doses (200 mg/m2 and 100 mg/m2) for induction and maintenance therapy. There was no significant difference in complete response rates, survival, or time to remission between the two doses. Higher doses were associated with higher therapy-related toxicity.
Paper Details　
Original Abstract of the Article :
Between 1982 and 1986, 326 evaluable patients with acute myeloid leukemia (AML) were randomized to receive cytarabine (Ara-C) at 200 mg/m2 (A200) or 100 mg/m2 (A100) for induction and maintenance therapy. Cycle 1 of induction therapy consisted of 7 days of continuous intravenous (IV) Ara-C and 3 day...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1824249

データ提供：米国国立医学図書館（NLM）

Cytarabine Dosing for Acute Myeloid Leukemia: A Camel's Guide to Navigating Cancer Treatment

Imagine a camel facing a challenging journey through a dangerous desert. This study investigates the optimal strategy for treating acute myeloid leukemia (AML), a challenging form of cancer. Researchers conducted a phase III trial comparing two different doses of cytarabine (Ara-C) in 326 patients with AML. The results showed no significant difference in survival rates between the two doses. This research, like a camel's ability to adapt to different desert landscapes, provides valuable insights into the complexities of cancer treatment, highlighting the need for personalized approaches tailored to individual patient needs.

Cytarabine Dosing: A Complex Landscape for AML Treatment

The study demonstrates that the choice of cytarabine dose for AML treatment is not a straightforward one. The findings suggest that the optimal dose may vary depending on individual patient characteristics. It's like recognizing that the best path through the desert depends on the camel's unique strengths and limitations.

What Does This Mean for Our Health?

The study highlights the importance of personalized medicine in cancer treatment. Understanding individual patient factors is crucial for choosing the most effective treatment strategies. It's like recognizing that the camel's journey is unique and requires a customized approach to ensure its safety and success.

Dr. Camel's Conclusion

The desert of cancer treatment is full of challenges and unknowns. This study provides a valuable reminder that personalized medicine is essential for navigating this complex landscape. Further research is needed to identify the optimal treatment strategies for different patient profiles. As we continue to explore the mysteries of cancer, we can learn from these studies to improve patient outcomes and ensure a more successful journey for those facing this challenging disease.

Date :
  1. Date Completed 1992-10-16
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

1824249

DOI: Digital Object Identifier

S0006-4971(20)76695-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.